Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 2
2011 2
2012 4
2013 3
2014 7
2015 3
2016 4
2017 5
2018 4
2019 1
2020 5
2021 11
2022 10
2023 6
2024 4
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Tumor localized agonistic anti-CD40 therapy and beyond.
Eltahir M, Persson H, Mangsbo S. Eltahir M, et al. Among authors: mangsbo s. Expert Opin Biol Ther. 2020 Mar;20(3):215-217. doi: 10.1080/14712598.2020.1713084. Epub 2020 Jan 10. Expert Opin Biol Ther. 2020. PMID: 31920122 No abstract available.
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.
Mebrahtu A, Laurén I, Veerman R, Akpinar GG, Lord M, Kostakis A, Astorga-Wells J, Dahllund L, Olsson A, Andersson O, Persson J, Persson H, Dönnes P, Rockberg J, Mangsbo S. Mebrahtu A, et al. Among authors: mangsbo s. Nat Commun. 2024 Nov 5;15(1):9542. doi: 10.1038/s41467-024-53839-5. Nat Commun. 2024. PMID: 39500897 Free PMC article.
MALT1 inhibition suppresses antigen-specific T cell responses.
Kerzeli IK, Nasi A, Fletcher E, Chourlia A, Kallin A, Finnberg N, Ersmark K, Lampinen M, Albertella M, Öberg F, Mangsbo SM. Kerzeli IK, et al. Among authors: mangsbo sm. Cell Immunol. 2024 Mar-Apr;397-398:104814. doi: 10.1016/j.cellimm.2024.104814. Epub 2024 Feb 24. Cell Immunol. 2024. PMID: 38422979 Free article.
Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.
Fletcher EAK, Cordfunke RA, Nasi A, Törnqvist G, Valentijn RRPM, Bergqvist A, Westhrin M, Rasch W, Lindqvist F, Dillmann I, Lord M, Bouwman N, Neefjes JJ, Franken KLMC, McArdle S, Ahmad M, Johansson S, Ossendorp F, Haggman M, Lampinen M, Ullenhag G, Ladjevardi S, Leja-Jarblad J, Lilleby W, Drijfhout JW, Mangsbo SM. Fletcher EAK, et al. Among authors: mangsbo sm. Mol Ther Oncol. 2025 Feb 20;33(2):200954. doi: 10.1016/j.omton.2025.200954. eCollection 2025 Jun 18. Mol Ther Oncol. 2025. PMID: 40520577 Free PMC article.
66 results